$30.3 Million is the total value of Memorial Sloan Kettering Cancer Center's 5 reported holdings in Q4 2022. The portfolio turnover from Q3 2022 to Q4 2022 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| No holdings reported for quarter Q4 2022 | ||||||||
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-02-10
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| VANECK VECTORS ETF TR | 12 | Q3 2023 | 80.9% |
| ORIC PHARMACEUTICALS INC | 12 | Q3 2023 | 14.8% |
| Y-MABS THERAPEUTICS INC | 12 | Q3 2023 | 9.6% |
| CARIBOU BIOSCIENCES INC | 8 | Q2 2023 | 19.5% |
| ILLUMINA INC | 8 | Q2 2023 | 4.4% |
| ROYALTY PHARMA PLC | 6 | Q1 2022 | 75.6% |
View Memorial Sloan Kettering Cancer Center's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Y-mAbs Therapeutics, Inc. | February 14, 2020 | 257,517 | 0.6% |
| Actinium Pharmaceuticals, Inc. | February 13, 2018 | 1,230,954 | 1.5% |
| Cactus Ventures, Inc. | January 18, 2013 | 5,702,387 | 34.7% |
View Memorial Sloan Kettering Cancer Center's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-10 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-14 |
| 13F-HR | 2021-11-15 |
| 13F-HR | 2021-08-16 |
View Memorial Sloan Kettering Cancer Center's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.